Specialised Therapeutics
Drug Stores & Pharmacies · Australia · 11-50 Employees
View Company Info for Free
Overview
Headquarters
PO Box 2299, Kew, Victoria, 3101, Austra...Website
www.stbiopharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Specialised Therapeutics
Specialised Therapeutics collaborates with global partners to introduce specialist medicines to patients in Australia, New Zealand, and Southeast Asia. The company focuses on commercializing therapies that address the unmet medical needs, particularly in the fields of endocrinology and oncology. With a commitment to high ethical standards, it has treated approximately 85,000 patients and contributed significantly to research and development. Its intended clients include healthcare providers and patients in the specialty medicine sector.Explore more
Popular SearchesSpecialised TherapeuticsStbiopharma.comMMedSc MIEAust CPEngSIC Code 51,512NAICS Code 42,424Show moreSpecialised Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Specialised Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Specialised Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Specialised Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Specialised Therapeutics
Click to see if Specialised Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Specialised Therapeutics launches new products
Check out if Specialised Therapeutics is spiking on competitors!
Specialised Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Specialised Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Specialised Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Specialised Therapeutics
Compare insights from companies similar to Specialised Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Specialised Therapeutics
<$5M
11-50
Private
-
-
KW
Kim WestonChief Financial Officer, Anz (South, East, Asia)
Company Profile Activity
Activity Insights
Specialised Therapeutics is experiencing very low activity levels compared to other companies in the Retail sector.
What does this means?
Specialised Therapeutics is drawing exceptional interest within the Retail industry, suggesting notable developments or strong market momentum, learn more about Specialised Therapeutics.
Specialised Therapeutics Tech Stack
A closer look at the technologies used by Specialised Therapeutics
See more technologies
Specialised Therapeutics News & Media
New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS
Minjuvi® (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen listed on the Pharmaceutical Benefits Scheme (PBS) for adults with relapsed or refractory follicular lymphoma (R/R...New First-in-Class Therapy for Chronic Graft-Versus-Host Disease Approved in Australia[1]
NIKTIMVO® (axatilimab) approved by the Therapeutic Goods Administration (TGA) under Priority Review for the treatment of eligible Australian patients with chronic graft-versus-host disease[2] Australia becomes the first country to obtain Marketing Authorisation for NIKTIMVO since approval...MINJUVI® (tafasitamab) for Relapsed or Refractory Follicular Lymphoma Approved in Australia
Minjuvi® (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen to be approved in Australia for adults with relapsed or refractory follicular lymphoma (R/R FL) (Grade 1-3a).1,2...New Combination Therapy for Advanced Small Cell, Lung Cancer Approved in Australia and Singapore
ZEPZELCA® (lurbinectedin), in combination with atezolizumab (Tecentriq®), is approved for use in Australia and Singapore as a first-line maintenance treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) [1],[2] SCLC is an aggressive form of lung cancer,...
Read more news
Top Drug Stores & Pharmacies Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Specialised Therapeutics
Sign Up For FreeTo access detailed company insights
Specialised Therapeutics collaborates with global partners to introduce specialist medicines to patients in Australia, New Zealand, and Southeast Asia. The company focuses on commercializing therapies that address the unmet medical needs, particularly in the fields of endocrinology and oncology. With a commitment to high ethical standards, it has t... Read More
